INITIAL PUBLIC ISSUE OF 27,00,000 EQUITY SHARES OF FACE VALUE OF RS. 10/- EACH ("EQUITY SHARES") OF GOLDLINE PHARMACEUTICAL LIMITED ("ISSUER" OR "THE "COMPANY") AT AN ISSUE PRICE OF RS. 43/- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF RS. 33/- PER EQUITY SHARE) FOR CASH, AGGREGATING TO RS. 1161.00 LAKHS ("PUBLIC ISSUE") OUT OF WHICH 1.38.000 EQUITY SHARES OF FACE VALUE OF RS. 10/- EACH, AT AN ISSUE PRICE OF RS. 43/- PER EQUITY SHARE FOR CASH, AGGREGATING RS. 59.34 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BYTHE MARKET MAKER TO THE ISSUE (THE 'MARKET MAKER RESERVATION PORTION '). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 25,62,000 EQUITY SHARES OF FACE VALUE OF RS. 10/- EACH. AT AN ISSUE PRICE OF RS. 43/- PER EQUITY SHARE FOR CASH, AGGREGATING RS. 59.34 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BYTHE MARKET MAKER TO THE ISSUE (THE 'MARKET MAKER RESERVATION PORTION '). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 25.62.000 EQUITY SHARES OF FACE VALUE OF RS. 10/- EACH. AT AN ISSUE PRICE OF RS. 43/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO RS. 1101.66 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 28.13% AND 26.69% RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

1, We rely entirely on third-party contract manufacturers for the manufacturing of our pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect our business, results of operations and financial condition.

2 The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting in the payment of late fees. Further, there have also been instances of erroneous filings made by our Company, in the past. While no regulatory actions or penalties have been imposed to date except below mentioned, there is no assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the Company or its directors/officers, It could negatively affect the Company's business and financial condition.

3. Our commercial success is largely dependent upon our ability to analyse the market of new pharmaceutical products, failure of which may have an adverse impact on our revenue and profitability.

4. There have been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by our Company, the Regulatory Authorities may impose monetary penalties on us or take certain punitive actions against our Company in relation to the same which may have adverse impact on our business, financial condition and results of operations.

5. We depend on our distributors for a significant portion of our revenue, and any decrease in revenues or sales from any one of our key intermediaries may adversely affect our business and results of operations. Our Company has a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its revenue If we are unable to maintain our relationship with such customers or if there is a reduction in their demand for our products, our business, results of operations and financial condition will be materially and adversely affected.

A. Cumulative Capital Private Limited has handled 6 public issues in the past three years and none of the issues closed below the issue price on listing date.

B. The average cost of acquisition per equity share by our Promoter is set forth in the table below:

C. Weighted Average Cost of Acquisition for all the Equity Shares transacted in one year, eighteen months and three years preceding the date of the Prospectus by all the shareholders:

D. The Price/Earnings ratio based on diluted EPS for fiscal 2025 for our Company at the upper end of the price band (i.e. 43 per Equity share) is 10.49 times.

E Weighted Average Return on Net Worth for fiscals 2025, 2024 and 2023 is 22.06%.

F. Weighted average cost of acquisition compared to floor price and cap price:

Final Demand: The summary of final demand as per BSE as on Bid closing date al different bid prices are provided below:

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE SME on Friday, May 15, 2026.

A. Allocation to Market Maker (After Rejections & Withdrawal): The Basis of Allotment to the Market Maker, at the Issue Price of Rs. 43/- per Equity Share, was finalized In consultation with BRLM and Stock Exchange The category was subscribed by 1.00 time. The total number of shares allotted In this category is 1,38,000 Equity shares. The details of the Basis of Allotment of the said category are as under:

B. Allocation to Individual Investors (After Rejections & Withdrawal): The Basis of Allotment to the Individual Investors, at the Issue price of Rs. 43/- per Equity Share, was finalized in consultation with BRLM and Stock Exchange. The category was subscribed 874.20 times i.e. for 9,00,000 Equity Shares. The total number of shares allotted in this category Rs. 9,00,000 Equity Shares to 150 successful applicants The details of the Basis of Allotment of the said category are as under

C. Allocation to Nil category (More than 2 lots to 1.000,000/-) (After Rejections & Withdrawal): The Basis of Allotment to Nil category (More than 2 tots to 1,000,000/-), at the Issue price of 143/- per Equity Share, was finalized in consultation with BR LM and Stock Exchange. The category was subscribed by 1012.67 times i.e. application received for 1,30,635,000 equity shares & the total number of shares allotted In this category is 1,29,000 Equity Shares to 14 successful applicants. The details of the Basis of Allotment of the said category are as under:

D. Allocation to Nil category (above Rs. 1,000,000/-) (After Rejections & Withdrawal): The Basis of Allotment to Nil category (above Rs. 1,000,000/-), at the Issue Price of Rs. 43/- per Equity Share, was finalized in consultation with BRLM and Stock Exchange. The category was subscribed 1986.59 times i.e. application received for 5,18,499,000 equity shares & the total number of shares allotted in this category is 2,61,000 Equity Shares to 29 successful applicants. The details of the Basis of Allotment of the said category are as under (on sample basis):

E. Allocation to QIBs Category- Mutual Fund and other (Excluding Anchor Investor) (Alter Rejections & Withdrawal): The Basis of Allotment to the Qualified Institutional Buyers (Excluding Anchor Investor), at the issue price of Rs. 43(/- per Equity Share, was finalized in consultation with BRLM The category received 67 applications for 96.993,000 Equity Shares, The total number of shares allotted in this category is 5,40,000 Equity Shares to 56 successful applicants. The details of the Basis of Allotment of the said category are as under:

F. Allocation to Anchor Investor (After Rejection): The Company In consultation with BRIM allotted 7.32,000 Equity Shares to 2 (two) Anchor Investors at an Issue Pi ice of ? 43A per share In accordance with SEBI (ICDR) Regulations. 2018. The details of the Basts of Allotment of the said category are as under

The- Board of Directors of our Company at its meeting held on May 15, 2026 has taken on record the basis of allotment of Equity Share s approved by the designated Stock Exchange, being BSE and has allotted the Equity Shares to various successful applicants The Allotment Advice Cum Refund Intimation have been mailed to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched / mailed for unblocking of funds and transfer to the Public issue Account an or before May 18, 2026. In case the same is not received within ten days, investors may contact the Registrar to the issue al the address given below, the Equity Shares allotted lo the successful allottees have been uploaded on May 18, 2026 far credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE and the trading of the Equity Shares Is expected to commence trading on May 19, 2026*

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to thorn in the Prospectus dated May 14, 2026 filed with the Registrar of Companies, Nagpur, Maharashtra

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, Bigshare Services Private Limited at ipo@bigshareonline.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sale applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged am) payment details a1 the address of the Registrar given below;